Nanomi Recognized for Excellence in Drug Delivery
Nanomi B.V., a prominent player in the life sciences sector and a subsidiary of the global pharmaceutical leader Lupin Limited, has achieved a significant milestone by winning the CMO Award for Life Science Leadership in Drug Delivery. This accolade was announced during the Drug, Chemical and Associated Technologies Association (DCAT) week, showcasing Nanomi's remarkable contributions to the field.
Redefining Industry Standards
The recognition of Nanomi's innovative approach to drug delivery underscores its mission of setting new benchmarks within the pharmaceutical industry. The processes developed by Nanomi are not only pioneering but are also aimed at transforming healthcare through advanced delivery systems. This award serves as both an affirmation of their hard work and a motivator to persist in their groundbreaking efforts.
Visionary Leadership
Dr. Shahin Fesharaki, the Global Chief Scientific Officer at Lupin, expressed pride in this achievement, stating, "This recognition underscores our dedication to advancing science and highlights Nanomi's pioneering efforts in drug delivery. We remain committed to innovation that enables the delivery of high-quality medicines that significantly improve patient outcomes." Such visionary leadership is essential in driving the company toward achieving its ambitious healthcare goals.
A Closer Look at the CMO Leadership Awards
The CMO Leadership Awards, introduced in 2011, are presented by Outsourced Pharma and Life Science Connect, with extensive research conducted to evaluate the top outsourcing partners in the industry. This year marks a pivotal change, as the awards have transitioned to a juried format, enhancing their prestige and ensuring recognition is based on merit and peer feedback.
About Lupin Limited
Lupin Limited, headquartered in Mumbai, India, stands as a global pharmaceutical leader, with its products distributed across more than 100 markets worldwide. The company's diverse expertise encompasses a wide range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. By maintaining a strong presence in India and the U.S., Lupin has positioned itself as a trusted resource in various therapy areas, such as respiratory issues, cardiovascular health, diabetes, anti-infectives, gastrointestinal conditions, central nervous system disorders, and women’s health. Boasting state-of-the-art manufacturing facilities and research centers globally, Lupin employs over 23,000 dedicated professionals, all focused on improving patient health through innovative solutions.
Commitment to Innovation
As part of their strategic vision, Lupin is dedicated to enhancing patient health outcomes not only through pharmaceuticals but also via their subsidiaries, including Lupin Diagnostics and Lupin Digital Health. This multi-faceted approach exemplifies their commitment to advancing healthcare and creating solutions that meet future health challenges.
Frequently Asked Questions
What is the CMO Award for Life Science Leadership?
The CMO Award for Life Science Leadership recognizes companies excelling in drug delivery and other pharmaceutical innovations.
Who is the parent company of Nanomi?
Nanomi is a subsidiary of Lupin Limited, a leading global pharmaceutical company.
What innovations has Nanomi introduced?
Nanomi has developed pioneering drug delivery systems that aim to improve healthcare outcomes and set industry benchmarks.
What does Lupin specialize in?
Lupin specializes in a wide array of products, including branded and generic formulations, complex generics, and biotechnology products.
How does Lupin contribute to healthcare?
Lupin contributes to healthcare by developing high-quality medications across multiple therapy areas and focusing on innovative healthcare solutions.
